adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial
23TH EHA, 11 - 15 Haziran 2018, (Tam Metin Bildiri)
- Yayın Türü: Bildiri / Tam Metin Bildiri
- Ankara Üniversitesi Adresli: Evet